{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:44:20Z","timestamp":1785743060972,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Patients with autoimmune rheumatic diseases, particularly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), experience excess cardiovascular risk that is not fully captured by conventional lipid measurements. In active RA, lower cholesterol may coexist with higher vascular risk, a pattern known as the lipid paradox. We propose that systemic inflammation can uncouple lipid concentration from lipoprotein function and organize the evidence along five mechanistic axes. Inflammatory cytokines, mainly interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), IL-1\u03b2, IL-17\/IL-23 and type I interferons, remodel lipoprotein metabolism. High-density lipoproteins (HDL) lose protective functions and may become pro-inflammatory. Apolipoprotein-B particles are oxidized or otherwise modified, linking lipid metabolism to autoimmunity. Macrophage cholesterol imbalance and cholesterol crystals activate inflammasome pathways in experimental atherosclerosis, while immune-cell metabolic rewiring may amplify cytokine output; these mechanisms are treated as extrapolated when direct rheumatic-disease evidence is limited. The pathways converge on endothelial dysfunction and thrombo-inflammation. RA and SLE are the mechanistic anchors, whereas psoriatic disease, axial spondyloarthritis, systemic sclerosis, vasculitides and antiphospholipid syndrome are weighted by evidence category. Standard lipid panels may therefore underestimate risk in selected contexts, especially during active inflammatory disease.<\/jats:p>","DOI":"10.3390\/biology15151270","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:17:40Z","timestamp":1785737860000},"page":"1270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid Immunometabolism in Autoimmune Rheumatic Diseases: Mechanistic Links Between Chronic Inflammation, Lipoprotein Dysfunction and Cardiovascular Risk"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6360-5653","authenticated-orcid":false,"given":"Luca","family":"Bonanni","sequence":"first","affiliation":[{"name":"Department of Medicine, Ospedale dell\u2019Angelo, 30016 Venice, Italy"},{"name":"Department of Medicine, University of Padua, 35131 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, 35131 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-020-04616-2","article-title":"The lipid paradox in rheumatoid arthritis: The dark horse of the augmented cardiovascular risk","volume":"40","author":"Venetsanopoulou","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.07.016","article-title":"Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis","volume":"128","author":"Drosos","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12265-020-09964-9","article-title":"Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis","volume":"13","author":"Halacoglu","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","article-title":"Novel Antiatherosclerotic Therapies","volume":"39","author":"Libby","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13,970 Contemporary High-Risk Patients With Statin Intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/acr.25537","article-title":"Metabolic Consequences of Rheumatoid Arthritis","volume":"77","author":"Barry","year":"2025","journal-title":"Arthritis Care Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow, D.I., Holmes, M.V., Kuchenbaecker, K.B., Engmann, J.E.L., Shah, T., Sofat, R., Guo, Y., Chung, C., and Peasey, A. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet, 379, 1214\u20131224.","DOI":"10.1016\/S0140-6736(12)60110-X"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105689","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation","volume":"169","author":"Westerterp","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2174\/0929867325666180316115726","article-title":"Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention","volume":"26","author":"Ossoli","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.rdc.2022.07.006","article-title":"Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases","volume":"49","author":"Ronda","year":"2023","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/art.41059","article-title":"High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/art.24677","article-title":"Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus","volume":"60","author":"McMahon","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/art.24802","article-title":"Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis","volume":"60","author":"Watanabe","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lee, J.J., Chi, G., Fitzgerald, C., Kazmi, S.H.A., Kalayci, A., Korjian, S., Duffy, D., Shaunik, A., Kingwell, B., and Yeh, R.W. (2021). Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.774418"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/ATVBAHA.118.311366","article-title":"Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque","volume":"39","author":"Shea","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"293","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1196\/annals.1361.077","article-title":"Systemic lupus erythematosus, atherosclerosis, and autoantibodies","volume":"1051","author":"Zampieri","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1194\/jlr.M200329-JLR200","article-title":"Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen","volume":"44","author":"Kobayashi","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/BOR.0000000000000667","article-title":"Deadliest catch: Neutrophil extracellular traps in autoimmunity","volume":"32","author":"Goel","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"178ra40","DOI":"10.1126\/scitranslmed.3005580","article-title":"NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis","volume":"5","author":"Khandpur","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.aaa8064","article-title":"Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis","volume":"349","author":"Warnatsch","year":"2015","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: Opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","article-title":"Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis","volume":"138","author":"Westerterp","year":"2018","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102813","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol crystals and inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12838","article-title":"Immunometabolism in the development of rheumatoid arthritis","volume":"294","author":"Weyand","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming","volume":"172","author":"Christ","year":"2018","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/ATVBAHA.114.303887","article-title":"Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes","volume":"34","author":"Bekkering","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/ATVBAHA.120.314212","article-title":"Trained Immunity: Long-Term Adaptation in Innate Immune Responses","volume":"41","author":"Tercan","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41581-023-00797-8","article-title":"Vascular damage in systemic lupus erythematosus","volume":"20","author":"Ambler","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0003319718814309","article-title":"The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis","volume":"70","author":"Bai","year":"2019","journal-title":"Angiology"},{"key":"ref_43","first-page":"400","article-title":"Systemic sclerosis and macrovascular involvement: Status of the issue in 2019","volume":"44","author":"Bertolino","year":"2019","journal-title":"J. Med. Vasc."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Toussirot, E., Gallais-S\u00e9r\u00e9zal, I., and Aubin, F. (2022). The cardiometabolic conditions of psoriatic disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.970371"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1759720X241271886","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: The role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rdc.2022.08.004","article-title":"Cardiovascular Disease in Large Vessel Vasculitis: Risks, Controversies, and Management Strategies","volume":"49","author":"Clifford","year":"2023","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ckj\/sfab229","article-title":"Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: A population-based cohort study","volume":"15","author":"Petrcich","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_48","first-page":"153","article-title":"Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis","volume":"5","author":"Kielstein","year":"2018","journal-title":"Eur. J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e002867","DOI":"10.1161\/JAHA.115.002867","article-title":"Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients","volume":"5","author":"Sharma","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/art.40892","article-title":"A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00018-022-04286-2","article-title":"Adipokines, adiposity, and atherosclerosis","volume":"79","author":"Liu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhao, T., Wei, Y., Zhu, Y., Xie, Z., Hai, Q., Li, Z., and Qin, D. (2022). Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1007165"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/15\/1270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:46:05Z","timestamp":1785739565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/15\/1270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":57,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biology15151270"],"URL":"https:\/\/doi.org\/10.3390\/biology15151270","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}